Advertisement CR Bard Q2 Net Income Up 44% - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CR Bard Q2 Net Income Up 44%

Net sales in the US and outside the US increased by 7% and decreased by 9%, respectively

CR Bard has reported an increase in net income by 44% to $112.2 million and diluted earnings per share of $1.11, an increase of 46%, for the second quarter of 2009.

The company has reported an increase in net sales by 1% to $624.6 million as compared to the net sales of prior year. Excluding the impact of foreign exchange, second quarter 2009 net sales increased 6% over the prior-year period.

Reportedly, for the second quarter of 2009, net sales in the US were $433.6 million, an increase of 7%, wheras net sales outside the US were $191 million, a decrease of 9%. Excluding the impact of foreign exchange, second quarter 2009 net sales outside the US increased 5%, over the prior-year period.

Timothy Ring, chairman and CEO of CR Bard, said: “We delivered another quarter of solid adjusted EPS growth despite continuing macroeconomic challenges. We are carefully managing our discretionary expenses while continuing to invest in R&D and business development to support our growth objectives. We believe that product leadership is the key to growth in our markets, and our commitment to this strategy remains unchanged.”